Revumenib (SNDX-5613)

Menin Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
BEAT-AML
(ven/aza combination)
Frontline KMT2Ar and
mNPM1 AML
INTERCEPT
(monotherapy)
MRD- progression in KMT2Ar and
mNPM1 AML
Colorectal Cancer
(monotherapy)
Unresectable metastatic microsatellite stable CRC

Axatilimab (SNDX-6352)

CSF-1R mAB
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)

Revumenib (SNDX-5613)

Menin Inhibitor

BEAT-AML

Frontline KMT2Ar and mNPM1 AML

Phase 1

INTERCEPT

MRD- progression in KMT2Ar and
mNPM1 AML

Phase 1

Colorectal Cancer

Unresectable metastatic microsatellite stable CRC

Phase 1

Axatilimab (SNDX-6352)

CSF-1R mAB

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor